Cystic Fibrosis Community — 9-12 Years Old

Games for Youth

Mucus Invaders

The lungs are on high alert, the mucus are invading! Get to battle stations and cut them down to size with the scissor-flinger and powerful back-claps.

• Play Mucus Invaders

Food Flip-Flop

Discover all the fun you can have by mixing up your tasty treats! The Food Flip-Flop is a fast paced puzzle that pits your wits, ingenuity and appetite against time.

• Play Food Flip-Flop

Word Scramble

Deoxyribo-what!? Think you know all those strange long words related to Cystic Fibrosis? Put your knowledge to the test with our Pulmozyme Word Scramble.

• Play Word Scramble

Indication and Usage

Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.

Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.

Pediatric Use

There is a limited amount of information available concerning the usage of Pulmozyme in patients who are younger than 5 years. The decision to use Pulmozyme in these patients is made after considering the potential for a benefit in lung function or in decreasing the risk of RTEs.

Important Safety Considerations

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to ≤10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. There were more reports of cough, moderate to severe cough, runny nose, and rash in the younger group of patients. Other reported events tended to be of mild to moderate severity. The kind of side effects reported was similar to that of Pulmozyme when used in the larger trials that studied older patients.

For further information, please see the Pulmozyme full prescribing information. If you have questions, please discuss them with your CF healthcare team.

Join the Community

Registering with our Cystic Fibrosis Community is fast and easy. Simply fill out the required information and then confirm your submission by entering in the two security words that appear in the text box. Soon you'll be part of our community!